香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 建議採納2025年A股員工持股計劃 緒言 本公司董事會謹此宣佈，其已於2025年8月20日舉行之董事會會議上審議通過 了員工持股計劃。員工持股計劃有待本公司股東會審議批准後方能生效。 《香港上市規則》涵義 員工持股計劃不涉及本公司（或其任何附屬公司）授予新A股或新A股的期權， 或發行A股。由於持股計劃涉及現有股份，因此須遵守《香港上市規則》第17章 第17.12條。 由於持有人涉及本公司若干董事、監事及最高行政人員，根據《香港上市規則》 第14A章，本公司董事、監事及最高行政人員各自參與員工持股計劃構成一項 關連交易。相關關連交易按個別基準計算的所有適用百分比率（定義見《香港上 市規則》）少於0.1%，因此彼等完全豁免股東批准、年 ...

截止8月20日收盘，东北电气(00042)、弘业期货(03678)、安德利果汁(02218)分列AH溢价率前三位，溢 价率分别为757.14%、252.72%、227.05%；宁德时代(03750)、恒瑞医药(01276)、美的集团(00300)分列 AH溢价率末三位，溢价率分别为-17.79%、-4.16%、5.63%。其中安德利果汁(02218)、京城机电股份 (00187)、弘业期货(03678)的偏离值位居前三，分别为29.98%、26.97%、24.92%；另外，比亚迪股份 (01211)、东北电气(00042)、龙蟠科技(02465)的偏离值位居后三，分别 为-120.45%、-72.35%、-52.95%。 前十大AH股溢价率排行 后十大AH股偏离值排行 | 股票名称 | H股(港元) | A股 | 溢价率↓ | 偏离值 | | --- | --- | --- | --- | --- | | 东北电气(00042) | 0.315 | 2.25 | 757.14% | -72.35% | | 弘业期货(03678) | 4.590 | 13.52 | 252.72% | 24.92% | | 安 ...

后十大AH股溢价率排行 | 股票名称 | H股(港元) | A股 | 溢价率↑ | 偏离值 | | --- | --- | --- | --- | --- | | 宁德时代(03750) | 404.800 | 277.83 | -17.79% | 1.44% | | 恒瑞医药(01276) | 79.000 | 64.1 | -2.81% | 1.95% | | 紫金矿业(02899) | 23.120 | 20.33 | 5.32% | -3.83% | | 美的集团(00300) | 82.600 | 72.68 | 5.40% | -4.64% | | 招商银行(03968) | 48.500 | 43.4 | 7.18% | 1.66% | | 潍柴动力(02338) | 16.620 | 15.26 | 9.99% | -0.64% | | 比亚迪股份(01211) | 114.000 | 107.63 | 13.09% | -128.72% | | 福耀玻璃(03606) | 58.600 | 55.77 | 13.99% | -3.44% | | 药明康德(02359) | 101.000 | ...

Core Viewpoint - Heng Rui Medicine has received acceptance for its drug application for Haiqubopai Ethanolamine Tablets from the National Medical Products Administration, aimed at treating chemotherapy-induced thrombocytopenia in adult patients [1][2] Group 1: Drug Approval and Clinical Trials - The National Medical Products Administration has issued an acceptance notice for the drug application of Haiqubopai Ethanolamine Tablets, which is indicated for adult patients with chemotherapy-induced thrombocytopenia [1] - The Phase III clinical trial (SHR8735-301) for Haiqubopai Ethanolamine Tablets achieved its primary endpoint in May 2025, demonstrating significant efficacy compared to the control group with good safety and tolerability [1] Group 2: Existing Approvals and Market Context - Haiqubopai Ethanolamine Tablets have previously been approved for two indications: chronic primary immune thrombocytopenia in adults with poor response to corticosteroids and immunoglobulins, and severe aplastic anemia in adults with poor response to immunosuppressive therapy [2] - The drug is an oral non-peptide thrombopoietin receptor (TPO-R) agonist that promotes platelet production through the activation of TPO-R mediated STAT and MAPK signaling pathways [2] - Similar products available in the international market include Eltrombopag, Avatrombopag, and Lusutrombopag, with a combined global sales forecast of approximately $2.59 billion for 2024 [2] - The cumulative R&D investment for Haiqubopai Ethanolamine Tablets has reached approximately 445.87 million yuan [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年8月18日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 申报阶段：上市 申请人：江苏恒瑞医药股份有限公司 证券代码：600276 ...

Group 1 - Company and its subsidiaries received approval from the National Medical Products Administration for clinical trials of HRS-4508 tablets, SHR-A1811 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [1] - HRS-4508 is a novel, efficient, selective tyrosine kinase inhibitor that inhibits tumor cell proliferation [1] - The total R&D investment for HRS-4508 project is approximately 36.42 million yuan [1] Group 2 - SHR-A1811 injection binds to HER2-expressing tumor cells and induces apoptosis through a unique mechanism [2] - SHR-A1811 was approved for use in treating adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 mutations [2] - The total R&D investment for SHR-A1811 project is approximately 1.26 billion yuan [2] Group 3 - Bevacizumab is a humanized anti-VEGF monoclonal antibody that has been approved in multiple countries since 2004 [3] - The global sales of Bevacizumab are projected to be approximately 5.655 billion USD in 2024 [3] - The total R&D investment for Bevacizumab injection project is approximately 3.45 million yuan [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年8月18日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 注射用瑞康曲妥珠单抗（注射用 SHR-A1811）可通过与 HER2 表 ...

智通财经APP获悉，截止8月18日收盘，东北电气(00042)、弘业期货(03678)、安德利果汁(02218)分列 AH溢价率前三位，溢价率分别为770.97%、223.53%、216.68%；宁德时代(03750)、恒瑞医药(01276)、 美的集团(00300)分列AH溢价率末三位，溢价率分别为-18.12%、-9.51%、6.30%。其中安德利果汁 (02218)、京城机电股份(00187)、农业银行(01288)的偏离值位居前三，分别为23.14%、14.77%、 12.52%；另外，比亚迪股份(01211)、东北电气(00042)、长飞光纤光缆(06869)的偏离值位居后三，分别 为-134.65%、-73.66%、-48.67%。 | 股票名称 | H股(港元) | A股 | 溢价率 | 偏离值↑ | | --- | --- | --- | --- | --- | | 比亚迪股份(01211) | 113.700 | 108.37 | 14.17% | -134.65% | | 东北电气(00042) | 0.310 | 2.25 | 770.97% | -73.66% | | 长飞光纤光缆 ( ...

截止8月15日收盘，东北电气(00042)、弘业期货(03678)、安德利果汁(02218)分列AH溢价率前三位，溢 价率分别为770.97%、226.69%、213.19%；宁德时代(03750)、恒瑞医药(01276)、紫金矿业(02899)分列 AH溢价率末三位，溢价率分别为-19.95%、-7.45%、5.81%。其中安德利果汁(02218)、金力永磁 (06680)、南京熊猫电子股份(00553)的偏离值位居前三，分别为21.03%、11.03%、10.63%；另外，比亚 迪股份(01211)、东北电气(00042)、龙蟠科技(02465)的偏离值位居后三，分别 为-143.50%、-80.62%、-50.25%。 前十大AH股溢价率排行 前十大AH股偏离值排行 | 股票名称 | H股(港元) | A股 | 溢价率 | 偏离值↓ | | --- | --- | --- | --- | --- | | 安德利果汁(02218) | 18.350 | 47.98 | 213.19% | 21.03% | | 金力永磁(06680) | 19.090 | 28.17 | 76.74% | 11.03% | ...

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]